Polycystic kidney disease (PKD) is an autosomal dominant genetic disorder that causes the formation of multiple cysts in the kidneys, leading to kidney failure. PKD is a common condition affecting approximately 1 in 500 individuals worldwide. The most prevalent type of PKD is autosomal dominant PKD (ADPKD). ADPKD is caused by mutations in either the PKD1 or PKD2 genes, which encode for proteins involved in cell growth and differentiation. These mutations lead to the formation of fluid-filled cysts in the kidneys, which can eventually lead to kidney failure. In addition to affecting the kidneys, PKD can also cause cysts in other organs, such as the liver, pancreas, and spleen. PKD can also lead to various complications, including high blood pressure, heart valve abnormalities, and brain aneurysms. This review focuses on the inheritance, pathophysiology, and treatment of PKD, with a specific emphasis on its effects on the cardiovascular system. Currently, there is no cure for PKD. However, several treatments are available to manage the symptoms and complications of the disease. These treatments include medications to control blood pressure, pain relievers, antibiotics for infections, and dialysis or kidney transplantation for kidney failure. Tolvaptan is the only FDA-approved drug specifically for ADPKD and has been shown to slow disease progression. In addition to summarizing current treatment options, this review will discuss promising future treatments, such as gene therapy and stem cell therapy.
References
[1]
Germino, G.G. and Guay-Woodford, L.M. (2015) Polycystic Kidney Disease: A Unifying Mechanism for Cyst Formation. Nature Reviews Nephrology, 11, 151-156.
[2]
Balat, A. (2016) Autosomal Dominant Polycystic Kidney Disease: Pathogenesis, Genetic Defects and Genotype-Phenotype Correlations. Nephrology Dialysis Transplantation, 31, 722-728.
[3]
Halvorson, C.R. (2010) Polycystic Kidney Disease: Inheritance, Pathophysiology, Prognosis, and Treatment. International Journal of Nephrology and Renovascular Disease, 3, 17-27.
[4]
Sautenet, B. (2020) Extrarenal Manifestations of ADPKD. Kidney International Reports, 5, 2044-2054.
[5]
Somlo, S. (2012) Genetics and Pathogenesis of Polycystic Kidney Disease. Journal of the American Society of Nephrology, 23, 1651-1653.
[6]
Rahbari Oskoui, F., Mrug, M., Saigusa, T. and Rizk, D.V. (2023) Cystic Diseases of the Kidney. In: Pyeritz, R.E., Korf, B.R. and Grody, W.W., Eds., EmeryandRimoin’sPrinciplesandPracticeofMedicalGeneticsandGenomics: Hematologic, Renal, and Immunologic Disorders, Elsevier, 39-94. https://doi.org/10.1016/b978-0-12-812534-2.00005-9
Willey, C., Kamat, S., Stellhorn, R. and Blais, J. (2019) Analysis of Nationwide Data to Determine the Incidence and Diagnosed Prevalence of Autosomal Dominant Polycystic Kidney Disease in the USA: 2013-2015. KidneyDiseases, 5, 107-117. https://doi.org/10.1159/000494923
[9]
Burgmaier, K., Kilian, S., Arbeiter, K., Atmis, B., Büscher, A., Derichs, U., et al. (2021) Early Childhood Height-Adjusted Total Kidney Volume as a Risk Marker of Kidney Survival in ARPKD. ScientificReports, 11, Article No. 21677. https://doi.org/10.1038/s41598-021-00523-z
[10]
Tublin, M., Nelson, J.B., Borhani, A.A., Furlan, A., Heller, M.T. and Squires, J. (2018) Polycystic Kidney Disease, Autosomal Recessive. In: Tublin, M., et al., Eds., ImaginginUrology, Elsevier, 106. https://doi.org/10.1016/b978-0-323-54809-0.50043-7
[11]
Sweeney, W.E., Gunay-Aygun, M., Patil, A. and Avner, E.D. (2015) Childhood Polycystic Kidney Disease. In: Avner, E.D., et al., Eds., PediatricNephrology, Springer, 1103-1153. https://doi.org/10.1007/978-3-662-43596-0_32
[12]
Schrier, R.W. (2012) Polycystic Kidney Disease. The New England Journal of Medicine, 366, 1899-1909.
[13]
Eroglu, E. (2019) Urinary Tract Infections in Patients with Autosomal Dominant Polycystic Kidney Disease. International Journal of Nephrology and Renovascular Disease, 12, 179-187.
[14]
Masoumi, A., et al. (2008) Proteinuria and the Progression of Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology, 3, 1768-1774.
[15]
Torra, R., et al. (2021) Autosomal Dominant Polycystic Kidney Disease. The Lancet, 397, 1903-1916.
Reiterová, J. and Tesař, V. (2022) Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment. InternationalJournalofMolecularSciences, 23, Article No. 3317. https://doi.org/10.3390/ijms23063317
[24]
Menezes, L.F. and Onuchic, L.F. (2006) Molecular and Cellular Pathogenesis of Autosomal Recessive Polycystic Kidney Disease. BrazilianJournalofMedicalandBiologicalResearch, 39, 1537-1548. https://doi.org/10.1590/s0100-879x2006001200004
[25]
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., et al. (2023) Targeting Integrin Pathways: Mechanisms and Advances in Therapy. SignalTransductionandTargetedTherapy, 8, Article No. 1. https://doi.org/10.1038/s41392-022-01259-6
[26]
Pei, Y. (2001) A “Two-Hit” Model of Cystogenesis in Autosomal Dominant Polycystic Kidney Disease? TrendsinMolecularMedicine, 7, 151-156. https://doi.org/10.1016/s1471-4914(01)01953-0
[27]
Shi, B., Akbari, P., Pourafkari, M., Iliuta, I., Guiard, E., Quist, C.F., et al. (2019) Prognostic Performance of Kidney Volume Measurement for Polycystic Kidney Disease: A Comparative Study of Ellipsoid vs. Manual Segmentation. ScientificReports, 9, Article No. 10996. https://doi.org/10.1038/s41598-019-47206-4
Wüthrich, R.P., Serra, A.L. and Kistler, A.D. (2009) Autosomal Dominant Polycystic Kidney Disease: New Treatment Options and How to Test Their Efficacy. KidneyandBloodPressureResearch, 32, 380-387. https://doi.org/10.1159/000254338
[30]
Cruz, N.M., Song, X., Czerniecki, S.M., Gulieva, R.E., Churchill, A.J., Kim, Y.K., et al. (2017) Organoid Cystogenesis Reveals a Critical Role of Microenvironment in Human Polycystic Kidney Disease. NatureMaterials, 16, 1112-1119. https://doi.org/10.1038/nmat4994
[31]
Tasneem, M., Mannix, C., Wong, A., Zhang, J. and Rangan, G. (2018) Is Serum Copeptin a Modifiable Biomarker in Autosomal Dominant Polycystic Kidney Disease? WorldJournalofNephrology, 7, 51-57. https://doi.org/10.5527/wjn.v7.i2.51
[32]
Peek, J.L. and Wilson, M.H. (2023) Cell and Gene Therapy for Kidney Disease. NatureReviewsNephrology, 19, 451-462. https://doi.org/10.1038/s41581-023-00702-3
[33]
Seliger, S.L., Watnick, T., Althouse, A.D., Perrone, R.D., Abebe, K.Z., Hallows, K.R., et al. (2020) Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial. Kidney360, 1, 1363-1372. https://doi.org/10.34067/kid.0004002020
[34]
Casarella, A., Nicotera, R., Zicarelli, M.T., Urso, A., Presta, P., Deodato, F., et al. (2021) Autosomic Dominant Polycystic Kidney Disease and Metformin: Old Knowledge and New Insights on Retarding Progression of Chronic Kidney Disease. MedicinalResearchReviews, 42, 629-640. https://doi.org/10.1002/med.21850
[35]
He, W., Xiao, W., Tan, Y., Zhao, X., Li, W., Zhang, Q., et al. (2018) Novel Mutations of PKD Genes in Chinese Patients Suffering from Autosomal Dominant Polycystic Kidney Disease and Seeking Assisted Reproduction. BMCMedicalGenetics, 19, Article No. 186. https://doi.org/10.1186/s12881-018-0693-7
[36]
Thatava, T., Armstrong, A.S., De Lamo, J.G., Edukulla, R., Khan, Y.K., Sakuma, T., et al. (2011) Successful Disease-Specific Induced Pluripotent Stem Cell Generation from Patients with Kidney Transplantation. StemCellResearch&Therapy, 2, Article No. 48. https://doi.org/10.1186/scrt89
[37]
Freedman, B.S., Lam, A.Q., Sundsbak, J.L., Iatrino, R., Su, X., Koon, S.J., et al. (2013) Reduced Ciliary Polycystin-2 in Induced Pluripotent Stem Cells from Polycystic Kidney Disease Patients with PKD1 Mutations. JournaloftheAmericanSocietyofNephrology, 24, 1571-1586. https://doi.org/10.1681/asn.2012111089
[38]
Somlo, S., Torres, V.E. and Caplan, M.J. (2013) Autosomal Dominant Polycystic Kidney Disease. In: Alpern, R.J., Moe, O.W. and Caplan, M., Eds., SeldinandGiebisch’sTheKidney, Elsevier, 2645-2688. https://doi.org/10.1016/b978-0-12-381462-3.00080-x
[39]
Schrier, A., et al. (2012) Disease in University Clinic of Nephrology and Haemodialysis of Cotonou: Clinical and Genetical Findings.
[40]
Shantanam, S. and Mueller (2018) HHS Public Access. Physiology & Behavior, 176, 139-148.
[41]
Hammond, S., Fick, M. and Johnson, M. (1995) In Autosomal. Liver, 5, 1349-1354.
[42]
Helal, I., Reed, B., Mettler, P., Mc Fann, K., Tkachenko, O., Yan, X., et al. (2012) Prevalence of Cardiovascular Events in Patients with Autosomal Dominant Polycystic Kidney Disease. AmericanJournalofNephrology, 36, 362-370. https://doi.org/10.1159/000343281
[43]
Pfeferman, M.B., Rocha, D.R.d., Rodrigues, F.G., Pfeferman, E. and Heilberg, I.P. (2022) Echocardiographic Abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients. JournalofClinicalMedicine, 11, Article No. 5982. https://doi.org/10.3390/jcm11205982
[44]
Lumiaho, A., Ikäheimo, R., Miettinen, R., Niemitukia, L., Laitinen, T., Rantala, A., et al. (2001) Mitral Valve Prolapse and Mitral Regurgitation Are Common in Patients with Polycystic Kidney Disease Type 1. AmericanJournalofKidneyDiseases, 38, 1208-1216. https://doi.org/10.1053/ajkd.2001.29216
[45]
Bremmer, M. (2010) Polycystic Kidney Disease: Inheritance, Pathophysiology, Prognosis, and Treatment. InternationalJournalofNephrologyandRenovascularDisease, 3, 69-83. https://doi.org/10.2147/ijnrd.s6939
[46]
Benjamin, L. (2023) Predictive Effects of Length of Treatment and Type of Dialysis on African Americans’ Quality of Life. Doctoral Dissertation, Walden University.
[47]
Perrone, R.D., Ruthazer, R. and Terrin, N.C. (2001) Survival after End-Stage Renal Disease in Autosomal Dominant Polycystic Kidney Disease: Contribution of Extrarenal Complications to Mortality. AmericanJournalofKidneyDiseases, 38, 777-784. https://doi.org/10.1053/ajkd.2001.27720
